scholarly journals Infrapatellar Fat Pad/Synovium Complex in Early-Stage Knee Osteoarthritis: Potential New Target and Source of Therapeutic Mesenchymal Stem/Stromal Cells

Author(s):  
Dylan N. Greif ◽  
Dimitrios Kouroupis ◽  
Christopher J. Murdock ◽  
Anthony J. Griswold ◽  
Lee D. Kaplan ◽  
...  
2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Yiqin Zhou ◽  
Haobo Li ◽  
Dong Xiang ◽  
Jiahua Shao ◽  
Qiwei Fu ◽  
...  

Abstract Introduction To evaluate the clinical efficacy of arthroscopic therapy with infrapatellar fat pad cell concentrates in treating knee cartilage lesions, we conducted a prospective randomized single-blind clinical study of controlled method. Methods Sixty cases from Shanghai Changzheng Hospital from April 2018 to December 2019 were chosen and randomly divided into 2 groups equally. Patients in the experiment group were treated through knee arthroscopy with knee infrapatellar fat pad cell concentrates containing mesenchymal stromal cells, while patients in the control group were treated through regular knee arthroscopic therapy. VAS and WOMAC scores were assessed at pre-operation, and 6 weeks, 12 weeks, 6 months, and 12 months after intervention. MORCART scores were assessed at pre-operation and 12 months after intervention. Results Twenty-nine cases in the experiment group and 28 cases in the control group were followed up. No significant difference in VAS, WOMAC, and MOCART scores were found between the two groups before surgery (P > 0.05). The WOMAC total and WOMAC function scores of the experiment group were significantly lower than those of the control group 6 months and 12 months after surgery (P < 0.05). The VAS rest and VAS motion scores of the experiment group were found significantly lower than those of the control group 12 months after surgery (P < 0.05). The MOCART scores of the experiment group were found significantly higher compared with the control group 12 months after surgery (P < 0.05). No significant difference in WOMAC stiffness scores were found between the two groups. Conclusions The short-term results of our study are encouraging and demonstrate that knee arthroscopy with infrapatellar fat pad cell concentrates containing mesenchymal stromal cells is safe and provides assistance in reducing pain and improving function in patients with knee cartilage lesions. Trial registration ChiCTR1800015379. Registered on 27 March 2018, http://www.chictr.org.cn/showproj.aspx?proj=25901.


2003 ◽  
Vol 412 ◽  
pp. 196-212 ◽  
Author(s):  
M. Quinn Wickham ◽  
Geoffrey R. Erickson ◽  
Jeffrey M. Gimble ◽  
T. Parker Vail ◽  
Farshid Guilak

Rheumatology ◽  
2018 ◽  
Vol 58 (3) ◽  
pp. 418-426 ◽  
Author(s):  
Julie E Davis ◽  
Robert J Ward ◽  
James W MacKay ◽  
Bing Lu ◽  
Lori Lyn Price ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e043088
Author(s):  
Zhaohua Zhu ◽  
Weiyu Han ◽  
Ming Lu ◽  
Jianhao Lin ◽  
Zongsheng Yin ◽  
...  

IntroductionThe infrapatellar fat pad (IPFP) is commonly resected during total knee arthroplasty (TKA) for better exposure. However, our previous studies have suggested that IPFP size was protective against, while IPFP signal intensity alteration was detrimental on knee symptoms and structural abnormalities. We hypothesise that an IPFP with normal qualities, rather than abnormal qualities, should be preserved during TKA. The aim of this study is to compare, over a 1-year period, the postoperative clinical outcomes of IPFP preservation versus resection after TKA in patients with normal or abnormal IPFP signal intensity alteration on MRI.Methods and analysisThree hundred and sixty people with end-stage knee osteoarthritis and on the waiting list for TKA will be recruited and identified as normal IPFP quality (signal intensity alteration score ≤1) or abnormal IPFP quality (signal intensity alteration score ≥2). Patients in each hospital will then be randomly allocated to IPFP resection group or preservation group. The primary outcomes are the summed score of self-reported Knee Injury and Osteoarthritis Outcome Score (KOOS), KOOS subscales assessing function in daily activities and function in sport and recreation. Secondary endpoints will be included: KOOS subscales (pain, symptoms and quality of life), Knee Society Score, 100 mm Visual Analogue Scale (VAS) Pain, timed up-and-go test, patellar tendon shortening, 100 mm VAS self-reported efficacy of reduced pain and increased quality of life, and Insall-Salvati index assessed on plain X-ray. Adverse events will be recorded. Intention-to-treat analyses will be used.Ethics and disseminationThe study is approved by the local Medical Ethics Committee (Zhujiang Hospital Ethics Committee, reference number 2017-GJGBK-001) and will be conducted according to the principle of the Declaration of Helsinki (64th, 2013) and the Good Clinical Practice standard, and in compliance with the Medical Research Involving Human Subjects Act . Data will be published in peer-reviewed journals and presented at conferences, both nationally and internationally.Trial registration numberThis trial was registered at Clinicaltrial.gov website on 19 October 2018 with identify number NCT03763448.


2020 ◽  
Vol 28 ◽  
pp. S298-S299
Author(s):  
Y. Satake ◽  
M. Izumi ◽  
K. Aso ◽  
N. Sugimura ◽  
Y. Igarashi ◽  
...  

2015 ◽  
Vol 24 (7) ◽  
pp. 1221-1232 ◽  
Author(s):  
Dah-Ching Ding ◽  
Kun-Chi Wu ◽  
Hsiang-Lan Chou ◽  
Wei-Ting Hung ◽  
Hwan-Wun Liu ◽  
...  

2014 ◽  
Vol 16 (4) ◽  
pp. R145 ◽  
Author(s):  
Weiyu Han ◽  
Shiji Cai ◽  
Zhenhua Liu ◽  
Xingzhong Jin ◽  
Xia Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document